Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
1978
3K+
LTM Revenue $600M
LTM EBITDA $71.2M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, Azenta reported last 12-month revenue of $600M and EBITDA of $71.2M.
In the same period, Azenta generated $278M in LTM gross profit and $26.7M in net income.
See Azenta valuation multiples based on analyst estimatesIn the most recent fiscal year, Azenta reported revenue of $594M and EBITDA of $39.5M.
Azenta expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Azenta valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $600M | XXX | $594M | XXX | XXX | XXX |
| Gross Profit | $278M | XXX | $270M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | $71.2M | XXX | $39.5M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $20.6M | XXX | -$21.7M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | $26.7M | XXX | -$55.8M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | -9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Azenta has current market cap of $1.8B, and EV of $1.5B.
As of January 19, 2026, Azenta's stock price is $40.
See Azenta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.8B | XXX | XXX | XXX | XXX | $0.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAzenta's trades at 2.6x EV/Revenue multiple, and 30.2x EV/EBITDA.
See valuation multiples for Azenta and 15K+ public compsAs of January 19, 2026, Azenta has market cap of $1.8B and EV of $1.5B.
Equity research analysts estimate Azenta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Azenta has a P/E ratio of 69.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | 30.2x | XXX | XXX | XXX |
| EV/EBIT | 75.2x | XXX | -199.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 69.0x | XXX | -56.1x | XXX | XXX | XXX |
| EV/FCF | 39.5x | XXX | 39.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAzenta's last 12 month revenue growth is 4%
Azenta's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Azenta's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Azenta's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Azenta and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | 98% | XXX | XXX | XXX |
| Rule of 40 | 8% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| ALS | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Azenta acquired XXX companies to date.
Last acquisition by Azenta was XXXXXXXX, XXXXX XXXXX XXXXXX . Azenta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Azenta founded? | Azenta was founded in 1978. |
| Where is Azenta headquartered? | Azenta is headquartered in United States of America. |
| How many employees does Azenta have? | As of today, Azenta has 3K+ employees. |
| Who is the CEO of Azenta? | Azenta's CEO is Mr. John P. Marotta. |
| Is Azenta publicy listed? | Yes, Azenta is a public company listed on NAS. |
| What is the stock symbol of Azenta? | Azenta trades under AZTA ticker. |
| When did Azenta go public? | Azenta went public in 1995. |
| Who are competitors of Azenta? | Similar companies to Azenta include e.g. Australian Clinical Labs, ALS, Healius, Integral Diagnostics. |
| What is the current market cap of Azenta? | Azenta's current market cap is $1.8B |
| What is the current revenue of Azenta? | Azenta's last 12 months revenue is $600M. |
| What is the current revenue growth of Azenta? | Azenta revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Azenta? | Current revenue multiple of Azenta is 2.6x. |
| Is Azenta profitable? | Yes, Azenta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Azenta? | Azenta's last 12 months EBITDA is $71.2M. |
| What is Azenta's EBITDA margin? | Azenta's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Azenta? | Current EBITDA multiple of Azenta is 21.8x. |
| What is the current FCF of Azenta? | Azenta's last 12 months FCF is $39.2M. |
| What is Azenta's FCF margin? | Azenta's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Azenta? | Current FCF multiple of Azenta is 39.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.